Article
Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays.
Cancer science - 1 Sept 2010
Yin C Cameron, Cortes Jorge, Galbincea John, Reddy Neelima, Breeden Megan, Jabbour Elias, Luthra Rajyalakshmi, Jones Dan
Abstract excerpt
Treatment of CML with the tyrosine kinase inhibitor (TKI) imatinib mesylate results in the emergence of point mutations within the kinase domain (KD) of the BCR-ABL1 fusion transcript. The introduction of next-generation TKIs that can overcome the effects of some BCR-ABL1 KD mutations requires quantitative mutation profiling methods to assess responses. We report the design and validation of such quantitative...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.